Hetero Biopharma launches ‘RILAST,’ the biosimilar Rituximab in Georgia.
Hetero Biopharma, the biologics arm of Hetero, launched the biosimilar Rituximab under the brand name ‘RILAST’ in Georgia with its strategic business partner M/s Zandra life sciences at Tbilisi, the capital city of Georgia, on 22nd January 2020.
Hetero Biopharma organised CME programme at Phnom Penh, Cambodia
Hetero Biopharma, the biologics arm of Hetero has recently held a CME program at Royal Phnom Penh hospital, under its knowledge sharing initiative “KBB (Knowledge Beyond Borders) hosted at Phnom Penh, Cambodia on 09th January 2020
Hetero Biopharma co-hosted and participated in BioAsia 2020 for the fourth consecutive year!!
BioAsia is a celebrated global platform that enhances, enriches and encourages newer innovations, path breaking discoveries and effective solutions in the biologics industry comprising of Biotech & Biopharma companies. Bio Asia 2020 talks about “today for tomorrow”, exploring the capabilities of life sciences companies to invest in Today to thrive and create value Tomorrow.
Hetero Biopharma organised live interactive Webinar sessions for Oncologists, Haematologist of Emerging markets.
Hetero Biopharma biologics arm of Hetero, with a mission of REACHing every stakeholder across the globe, organised webinars (Web based CMEs) under its knowledge exchange platform KBB (Knowledge Beyond Borders) for oncologists, haematologists of Asia and Africa
3rd Live interactive webinar session for Nephrologists connecting the continents by Hetero Biopharma
Hetero Biopharma, the biologics arm of Hetero, after successful completion of two webinars for Oncologists and with a mission of REACH-ing every partner, prescriber organized third consecutive interactive webinar session under its knowledge exchange platform KBB(Knowledge Beyond Borders) on “Kidney disease & Renal Replacement Therapy in times of Novel Corona Virus Disease 2019(COVID-19) pandemic
Hetero Biopharma organized a consecutive session for renal nurses on “Right way of doing Dialysis & Importance of managing Anemia in CKD”
As a tribute for the untiring efforts put in nurses for the betterment of world, WHO has recognised 2020 as “International Year of Nurses”. Being a healthcare professional, it is important to be updated in their respective field of operations, In continuation to the same Hetero Biopharma has organised a webinar on 06-06-2020 for renal nurses and dialysis staff on “Right way of doing dialysis & importance of managing anaemia in CKD”
Hetero Biopharma organized Cancer Survivors day gatherings across Asia and Africa
Hetero Biopharma, biologics arm of Hetero has structured Cancer Survivors day activities across the emerging markets of Asia and Africa on 7th June for the first time, with the theme Celebration of life.
Hetero Biopharma organized webinar involving Strategic Business Partners from the regions of Asia, Africa, CIS and LATAM
Covid – 19 season turned out to be learning time to all of us. Hetero Biopharma Global Business team has been working relentlessly to engage 3P’s (Patients, Partners &Prescribers) of our Business. We realized that there is a need of sharing biosmilar value addition to Business Partners. To address this need we have organised a webinar to all our partners in over 75 countries across all the region of emerging markets.
Hetero Biopharma organized a web based interactive session on “Role of TNF blockers in Rheumatoid arthritis” and “Rituximab use in Rheumatoid arthritis- The Nigerian Experience”
Rheumatoid arthritis is an auto immune disorder affecting 8% of global population and 1% of Indian population. Across the globe Health care professionals approach multiple models of treating this disease. Hetero Biopharma with a motto REACHing the stakeholders that include 3P’s – Prescribers, Partners, & Patients organized a webinar under its Knowledge exchange platform KBB –(Knowledge Beyond Borders) on 03rd July 2020 connecting the Rheumatologists from Asia, Africa, CIS and LATAM
Hetero Biopharma raised awareness on Brain cancer across the emerging markets of Africa and Asia on Glioblastoma day
Glioblastoma Awareness Day (GBM Day) is dedicated to increasing public awareness of glioblastoma, the most common and aggressive form of brain cancer. It also honours those who have been impacted by the disease and supports efforts to develop better treatment options that will improve patient’s long-term prognosis.
Lung cancer awareness raised across the emerging markets on World Lung cancer day by Hetero Biopharma
Lung cancer is the most common cancer worldwide. It is the most common cause of cancer in men worldwide. Lung cancer is responsible for nearly 1 in 5 cancer deaths. Occurs most commonly between 40-70 yrs of age with peak incidence at 50s or 60s
Awareness Programmes on CKD organized in Sri Lanka
Hetero Biopharma – the biologics arm of Hetero Group in collaboration with its strategic business partner George Stuart Health Ltd had organized a community awareness programme on Chronic
BECON Pharma – Hetero Biopharma’s Business partner in Bangladesh launched Darbepoetin Alfa in Dhaka, Bangladesh under the brand name of DARBESIS.
Hetero Biopharma (HBP) – the biologics arm of Hetero Group in collaboration with Beacon Pharmaceuticals, one of the largest pharmaceutical companies in Bangladesh launched Darbepoetin alfa under the brand name ‘Darbesis’.
Customized Key Opinion Meet organized for Nephrologists at Phnom Penh Cambodia
Hetero Biopharma organized a customized biologics discussion session on therapeutic advancement in anaemia in Chronic Kidney Disease (CKD) and on Chemotherapy Induced Anaemia (CIA), under its knowledge Sharing Initiative ‘Knowledge Beyond Barriers (KBB) in Phnom Penh, capital city of Cambodia.
Hetero Biopharma participated in 16th Joint AFRAN/APNA Annual scientific conference at Mombasa Kenya
Hetero Biopharma, biologics arm of Hetero, associated with The Kenya Renal Association in organizing “16th Joint AFRAN (African Association of Nephrology) / APNA (African Paediatric Nephrology Association) annual scientific conference hosted at Mombasa, Kenya from 25 to 28 September.
Hetero Biopharma participated in 4th Annual Conference of Cambodian Association of Nephrology
Hetero Biopharma Ltd, a Biologics arm of Hetero group recently participated in 4th Annual Conference of Cambodian Association of Nephrology, which was hosted in Phnom Penh, Cambodia on 24th August 2019. More than 250 delegates comprising Health care professionals from Cambodia and speakers from India, Japan, Germany, Thailand from multiple specialities, majorly from the field of Nephrology, Haematology, and Oncology.
Hetero Biopharma launched Derise in Sri Lanka- Rise of first Darbepoetin in Sri Lanka
We are pleased to inform you that Hetero Biopharma – the Biologics arm of Hetero Group has recently launched ‘Derise’ (Darbepoetin Alfa) in Colombo, the capital city of Sri Lanka on 19th Jan 2019.
Hetero Biopharma Organised INCON 2019 (International Conclave of Oncology) at Hyderabad
Hetero Biopharma- the biologics arm of Hetero group has organised its first “International Conclave of Oncology” (INCON 2019) part of its knowledge sharing initiative “Knowledge Beyond borders(KBB)” on 29th January 2019 at Hyderabad.
Hetero Biopharma – Awarded in the category of “Excellence in Pharma Packaging”
Hetero Biopharma, the biologics arm of Hetero Group was awarded with “Excellence in Pharma: Packaging” for its anti-counterfeiting and safety packaging in a seminar held on “Anti-counterfeiting & Compliance and Awards”. This event was organised by Realmed solutions Pvt. Ltd. in collaboration with Ministry of Medical and Health, Government of Telangana on 21st of June 2019 at Novotel, Hyderabad.
Hetero Biopharma organised Paramedical Staff Debut education programme @ Uganda
Hetero Biopharma, a biologics arm of Hetero has organized first of its kind, customized workshop on the challenges faced by dialysis nurses in their day to day practice on 18th October at Piato Restaurant Kampala.
Hetero Biopharma participated in 7th Conference of Myanmar society of Haematology 2019
Hetero Biopharma Ltd, a biologics arm of Hetero group, has participated in 7th Conference of Myanmar society of Haematology 2019 organised by Myanmar Medical association held at Yangon, Myanmar on 21st & 22nd September in collaboration with our distribution partner ABC international.
Hetero Biopharma participated in Sri Lanka College of Haematologists Session 2019
Hetero Biopharma Ltd, a Biologics arm of Hetero group, in collaboration with our strategic business partner Divasa Pharma, recently participated in Sri Lanka College of Haematologists session 2019, organized in Colombo, Sri Lanka on 18th September 2019. More than 200 Health care professionals across Haematology, Oncology and other specialities actively participated in the event.
Hetero Biopharma launches RILAST - 1st Rituximab Biosimilar in Uzbekistan.
Hetero Biopharma, the biologics wing of Hetero has recently launched RILAST- Rituximab in Uzbekistan, in alliance with our strategic business partner NF pharma. The launch event was hosted in Hotel…at Tashkent on 11th of December 2019.
Hetero Biopharma at BIOASIA 2018
Hetero Biopharma – the Biologics arm of Hetero Group for the second time had participated in Bioasia 2018 – the annual flagship event organized by the Government of Telangana. A three-day event which was held from February 22nd – 24th, at HICC Hyderabad, brought together around 1500 delegates from over 50 countries with 100 speakers and 800 corporates.
Hetero Biopharma launched Rilast (Rituximab) in Georgia – the first Biosimilar Rituximab in Georgia
Hetero Biopharma – the Biologics arm of Hetero Group has recently launched ‘Rilast’ (Rituximab) in Tbilisi, the capital city of Georgia on 28th Jan 2018. Rilast is the first Biosimilar Rituximab in Georgia.
Hetero Cancare launched 5 Oncology products in Philippines.
Hetero Hetero corporate was launched in Manila 28th October, by his highness Mr L.D. RALTE (Indian Ambassador in Philippines) in the presence of Mr. Manoj Sihag -Country manager, NSM – MS. Carol Pantoja & Other colleagues. This event served a great platform to Showcase Hetero as a research oriented company entering to Philippines.
Hetero Biopharma at Kenya Renal Association (KRA)- 2018
Hetero Biopharma recently participated in Kenya Renal Association (KRA) conference - 2018, which is recognized to be a major annual knowledge platform in East Africa. This conference was organized for several leading nephrologists from east African countries namely Kenya, Uganda, Tanzania etc. The conference was scheduled from 27th – 30th Sept 2018. During this conference, Dr Ahmed Sokhwala, Asst. Professor & Consultant Nephrologist, Dept. – Nephrology, The Aga Khan University & Hospital –
Hetero Biopharma launched Rilast (Rituximab) in Mayanmar
Hetero Biopharma – the Biologics arm of Hetero Group has recently launched ‘Rilast’ (Rituximab) in Yangon, the largest city of Myanmar on 27th Oct’ 2018. Rilast is the second Biosimilar (Rituximab) in Myanmar and Bevaas (Bevacizumab) is also expected to be shortly. Spearheaded by Dr. Praveen Shetty (DGM, Global Clinical Strategy & Medico Marketing), and Mr. Rajeev Rawal, Executive Director ABC International Ltd – Hetero’s business partner in Myanmar – the product Rilast was launched in the presence of leading Haematologists & Oncologists
Hetero Biopharma’s 1st commercial launch in Global Markets -launch of Derise (Darbepoetin Alfa) in Cambodia.
Hetero Biopharma – the Biologics arm of Hetero Group has recently launched ‘Derise’ (Darbepoetin Alfa) in Phnom Penh, the capital city of Cambodia on 18th May 2017. Cambodia is the 1st market to get approval of Derise (Darbepoetin Alfa) and Rilast (Rituximab) approval is expected shortly.
Hetero Biopharma launched Derise (Darbepoetin Alfa) in Kenya – 2nd Commercial launch in Global Markets.
Hetero Biopharma – the Biologics arm of Hetero Group has recently launched ‘Derise’ (Darbepoetin Alfa) in Nairobi, the capital city of Kenya on 29th June 2017. Kenya is the 2nd market to launch Derise (Darbepoetin Alfa) commercially and Rilast (Rituximab), Bevaas (Bevacizumab) launches are expected shortly.
Hetero Biopharma @ Kenya Renal Association (KRA).
In continuation to the successful launch of Derise (Darbepoetin Alfa) in Kenya, Hetero Biopharma recently participated in Kenya Renal Association (KRA) conference, which is recognized to be a major annual knowledge platform in East Africa. This conference was organized for several leading nephrologists from east African countries namely Kenya, Uganda, Tanzania etc.